Latest Product News
Jet-Printing Microfluidic Devices on Demand
Jet-printing microfluidic devices on-demand describes a game-changing method to generate cell-friendly microfluidic devices on demand.
OGT Expands NGS Cancer Panel Offering
Oxford Gene Technology has today announced the expansion of its SureSeq™ range of next-generation sequencing panels.
PerkinElmer To Acquire Cell Engineering Company Horizon Research
PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Horizon Discovery Group plc (LSE: HZD) have announced an agreed investment to be used for advancing their life sciences and genomics technology departments.
Mogrify Introduces EpiMOGRIFY To Identify Epigenetic Switches
Mogrify Limited (Mogrify®) today announced the introduction of EpiMOGRIFY. The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion.
Bio-Rad Launches CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems and BR.io Software
Bio-Rad Laboratories, Inc. today announced the global launch of its CFX Opus 96 and CFX Opus 384 Real-time PCR Systems along with BR.io, a cloud-based instrument connectivity, data management, and analysis platform.
10x Genomics Signs Agreement to Acquire ReadCoor
10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a definitive agreement to acquire ReadCoor, Inc., for cash and stock consideration of $350 million. The announcement follows 10x Genomics’ acquisition of Stockholm-based CartaNA AB, developers of In Situ RNA analysis technology,
Daicel Arbor Biosciences Introduces myBaits® Custom Methyl-Seq
Daicel Arbor Biosciences, a division of Chiral Technologies, Inc., announces the launch of their new line of myBaits Custom Methyl-Seq target capture kits. This pairs an innovative methyl-seq probe design algorithm with a highly optimized target capture protocol to efficiently enrich target genes and markers of interest from converted methyl-seq NGS libraries.
New Collaboration Explores Efficacy of Gene Delivery Vector Tech in Diabetes and Multiple Sclerosis
Amarna Therapeutics has announced today that it has entered into a collaboration with scientists from the Progreso y Salud Foundation (FPS) at Cabimer in Seville, to jointly examine the efficacy of Amarna’s SVec™ gene delivery vector for the development of effective immunotherapies for diabetes mellitus type 1 (DM1) and multiple sclerosis (MS).
First Data on Using a Therapeutic Form of ACE2 To Treat COVID-19 Published
A case report published today in The Lancet Respiratory Medicine outlines the first compassionate use of recombinant soluble human ACE2 (APN01) to treat a female 45-year-old patient who was diagnosed with severe COVID-19.
Canada’s Largest Research Hospital Selects ImmunoGenomiX Platform To Analyze Immune Sequencing Data
ENPICOM, an innovative bioinformatics software engineering company specialized in decoding the immune system, announced that the Princess Margaret Cancer Centre of the University Health Network (UHN) has purchased a subscription to ENPICOM’s data analysis platform.